Fmoc-Lys(Mtt)-OH

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: Fmoc-Lys(Mtt)-OH
• 英文别名: Fmoc-D-Lys(Mtt)-OH；2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[[(4-methylphenyl)-diphenylmethyl]amino]hexanoic acid
• 化学式: C₄₁H₄₀N₂O₄
• 分子量: 624.78
• InChiKey: YPTNAIDIXCOZAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  47
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Fmoc-Lys(Mtt)-OH 、 4-[(1Z,4Z,9Z,15Z)-10,15,20-Tris-(2,6-dichloro-phenyl)-porphyrin-5-yl]-benzoic acid 生成 2-Amino-6-{4-[(1Z,4Z,9Z,15Z)-10,15,20-tris-(2,6-dichloro-phenyl)-porphyrin-5-yl]-benzoylamino}-hexanoic acid
  参考文献：
  名称：

  A Facile Solid-Phase Strategy for the Synthesis of Oligonucleotide-Tetraphenylporphyrin Conjugates

  摘要：

  DOI：

  10.1002/(sici)1099-0690(200003)2000:6<1013::aid-ejoc1013>3.0.co;2-3

文献信息

• [EN] METHODS OF MAKING INCRETIN ANALOGS<br/>[FR] PROCÉDÉS DE FABRICATION D'ANALOGUES D'INCRÉTINE
  申请人：LILLY CO ELI

  公开号：WO2021034815A1

  公开（公告）日：2021-02-25

  Intermediate compounds are disclosed for making incretin analogs, or pharmaceutically acceptable salts thereof. In addition, methods are disclosed for making incretin analogs by coupling from two to four of the intermediate compounds herein via hybrid liquid solid phase synthesis or native chemical ligation.

  本发明公开了制备胰高血糖素类似物或其药用可接受盐的中间化合物。此外，本发明还公开了通过混合液固相合成或天然化学连接法，通过将本文中的两到四种中间化合物耦合制备胰高血糖素类似物的方法。
• Direct ratiometric detection of nitric oxide with Cu(<scp>ii</scp>)-based fluorescent probes
  作者：A. Loas、S. J. Lippard

  DOI：10.1039/c7tb02666h

  日期：——

  We report the first Cu(II)-based fluorescent sensors for ratiometric detection of nitric oxide. The two probes operate by energy transfer between hydroxycoumarin and fluorescein chromophores, contain polyproline or piperazine as rigid spacers, and elicit a rapid and selective ratiometric response upon direct reaction with nitric oxide.

  我们报告了第一批基于Cu（II）的荧光传感器，用于一氧化氮的比例检测。这两种探针通过羟基香豆素和荧光素生色团之间的能量转移进行操作，包含聚脯氨酸或哌嗪作为刚性间隔基，并在与一氧化氮直接反应时引起快速和选择性的比例响应。
• Growth Hormones with Prolonged In-Vivo Efficacy
  申请人：Novo Nordisk HealthCare AG

  公开号：US20180221501A1

  公开（公告）日：2018-08-09

  The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

  本发明涉及优化了亚皮下注射的多肽化合物，例如具有连接剂的生长激素偶联物，该连接剂提供与白蛋白的非共价结合。
• Spectral Properties of Pro‐multimodal Imaging Agents Derived from a NIR Dye and a Metal Chelator
  作者：Zongren Zhang、Samuel Achilefu

  DOI：10.1562/2005-06-08-ra-568

  日期：2005.11

  Monomolecular multimodal imaging agents (MOMIAs) are able to provide complementary diagnostic information of a target diseased tissue. We developed a convenient solid‐phase approach to construct two pro‐MOMIAs (before incorporating radiometal) derived from 1,4,7,10‐tetraazacy‐clododecane‐1,4,7,10‐tetraacetic acid (DOTA) and cypate, a near‐infrared (NIR) fluorescent dye analogous to indocyanine green (ICG). The possible interaction between d orbitals of transition metal DOTA complexes or free metals and the p orbitals of cypate chromophore could quench the fluorescence of pro‐MOMIAs. However, we did not observe significant changes in the spectral properties of cypate upon conjugation with DOTA and subsequent chelation with metals. The fluorescence intensity of the chelated and nonmetal‐chelated PRO‐MOMIAs remained fairly the same in dilute 20% aqueous dimethylsulfoxide (DMSO) solution (1 × 10⁻⁶M). Significant reduction in the fluorescence intensity of pro‐MOMIAs occurred in the presence of a large excess of metal ions (> 1 molar ratio for indium and 20‐fold for a copper relative to pro‐MOMIA). This study suggests the feasibility of using MOMIAs for combined optical and radioisotope imaging.

  摘要分子多模态成像剂（MOMIAs）能够提供目标病变组织的互补诊断信息。我们开发了一种简便的固相方法来构建两种原 MOMIAs（在加入放射性金属之前），它们分别来自 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸（DOTA）和一种类似于吲哚菁绿（ICG）的近红外（NIR）荧光染料环酯。过渡金属 DOTA 复合物或游离金属的 d 轨道与环磷酸酯发色团的 p 轨道之间可能存在相互作用，这可能会淬灭原 MOMIAs 的荧光。然而，我们并没有观察到环磷酸酯与 DOTA 共轭以及随后与金属螯合时光谱特性的明显变化。在 20% 的二甲基亚砜（DMSO）稀释水溶液（1 × 10-6M）中，螯合和非金属螯合的 PRO-MOMIAs 的荧光强度基本相同。在金属离子大量过剩的情况下（铟的摩尔比为 1，铜的摩尔比为原 MOMIA 的 20 倍），原 MOMIA 的荧光强度会显著降低。这项研究表明，利用 MOMIAs 进行光学和放射性同位素联合成像是可行的。
• Growth Hormones With Prolonged In-Vivo Efficacy
  申请人：Behrens Carsten

  公开号：US20120309944A1

  公开（公告）日：2012-12-06

  The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.

  本发明涉及具有持续作用的生长激素化合物。通过将一种结合白蛋白残基的氢亲和性间隔物与生长激素变体连接，实现了该效果。此外，还描述了制备和使用这些化合物的方法。这些生长激素化合物基于其改变的特征，被认为在治疗中特别有用。